Basic Information

Gene symbol VEGFA Synonyms L-VEGF, MVCD1, VEGF, VPF Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description vascular endothelial growth factor A

GTO ID GTC0100
Trial ID NCT01189461
Disease Diabetic Retinopathy | Diabetic Macular Edema
Altered gene VEGFA
Therapeutic/Target gene Target gene
TherapyAptamer
Treatment Macugen|pegaptanib|EYE001
PhasePhase3
Recruitment statusCompleted
TitleAn Open Label, One Year, Non-Comparative Study To Evaluate The Safety And Tolerability Of Intravitreous Pegaptanib Sodium In Patients With Diabetic Macular Edema
Year2011
CountryFinland|Spain|Sweden|United Kingdom
Company sponsorPfizer
Other ID(s)A5751036

Clinical Result

Cohort 1
Administration route intravitreal injection
Dosage pegaptanib sodium, 0.3 mg, up to a maximum of 48 weeks, the minimum dosing interval between injections will be at least 6 weeks
Pts 46
Age Adult, Older_Adult
Outcome Incidence of Ocular and Non-Ocular Adverse Events (AEs):Ocular AEs Measure Type: Number:10; Non-ocular AEs:8|Mean Total Number of Injections:Mean (Standard Deviation):3.24(1.037)
Adverse reactions 3/46(Cardiac disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders)
References PMID: 25187694

Relationship Graph

Overview of Knowledge Graph